Premium
A multicentre study of primary breast diffuse large B ‐cell lymphoma in the rituximab era
Author(s) -
Hosein Peter J.,
Maragulia Jocelyn C.,
Salzberg Matthew P.,
Press Oliver W.,
Habermann Thomas M.,
Vose Julie M.,
Bast Martin,
Advani Ranjana H.,
Tibshirani Robert,
Evens Andrew M.,
Islam Nahida,
Leonard John P.,
Martin Peter,
Zelenetz Andrew D.,
Lossos Izidore S.
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12753
Subject(s) - rituximab , medicine , lymphoma , oncology
Summary Primary breast diffuse large B ‐cell lymphoma ( DLBCL ) is a rare subtype of non‐ H odgkin lymphoma ( NHL ) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system ( CNS ) relapses. Data was retrospectively collected on patients from 8 US academic centres. Only patients with stage I / II disease (involvement of breast and localized lymph nodes) were included. Histologies apart from primary DLBCL were excluded. Between 1992 and 2012, 76 patients met the eligibility criteria. Most patients (86%) received chemotherapy, and 69% received immunochemotherapy with rituximab; 65% received radiation therapy and 9% received prophylactic CNS chemotherapy. After a median follow‐up of 4·5 years (range 0·6–20·6 years), the K aplan– M eier estimated median progression‐free survival was 10·4 years (95% confidence interval [ CI ] 5·8–14·9 years), and the median overall survival was 14·6 years (95% CI 10·2–19 years). Twelve patients (16%) had CNS relapse. A low stage‐modified I nternational P rognostic I ndex ( IPI ) was associated with longer overall survival. Rituximab use was not associated with a survival advantage. Primary breast DLBCL has a high rate of CNS relapse. The stage‐modified IPI score is associated with survival.